In: Comunicado de prensa

Jonathan Santomauro obtuvo el reconocimiento por su dedicación a la compañía y la comunidad en la lista anual dinámica de nuevos y permanentes del Philadelphia Business Journal.

HORSHAM, PA. — 17 de abril de 2018. Ancillare, LP, líder global en suministros clínicos y complementarios, la única organización exclusivamente dedicada a atender integralmente las necesidades de gestión de la cadena de suministro clínica y complementaria para compañías grandes y medianas del sector farmacéutico, biotecnológico y de dispositivos, al igual que organizaciones de investigación por contrato y médicas, se complace en anunciar que Jonathan Santomauro, su presidente y cofundador, ha sido reconocido por el Philadelphia Business Journal como el homenajeado “40 Under 40” del 2018.

Este galardón reconoce a los líderes actuales y futuros de la región de Filadelfia por su excelencia profesional, éxito sobresaliente y sus contribuciones a la comunidad Santomauro fue seleccionado entre más de 400 postulados.

Santomauro tuvo un papel decisivo al definir el enfoque particular del sector de la gestión de la cadena de suministro clínica y complementaria, y más notablemente reconocido por ser el promotor de la solución integral de Operación Llave en Mano Ancillare (A-TKO™), que ha revolucionado la forma como la industria aborda su cadena de suministro clínica. Mediante este y otros modelos de negocios, Ancillare continúa a la cabeza de la industria global de la cadena de suministro médica, y continuará teniendo un impacto directo en las operaciones, cronogramas, rendimiento de las instalaciones y experiencias de los pacientes de los ensayos clínicos.

Ancillare ha crecido desde una compañía emergente para convertirse en una organización global con más de 200 empleados en todo el mundo. Hoy en día, ocho de las diez principales compañías farmacéuticas globales, tres de las cinco primeras compañías de tecnología a nivel mundial y dos de las principales organizaciones de investigación clínica del mundo confían en Ancillare para la gestión de sus necesidades de suministro clínico y complementario para sus ensayos clínicos Fase I-IV.

“Ser nombrado uno de los ’40 Under 40′ del Philadelphia Business Journal es todo un honor”, afirmó Santomauro. “Soy afortunado de tener una carrera que tiene impacto directo en las operaciones de los ensayos clínicos y en el desarrollo de terapias innovadoras para pacientes de todo el mundo”.

Participante activo en la comunidad empresarial local, como miembro del capítulo de Philadelphia de YPO (anteriormente Young Presidents Organization), y miembro de larga data del Consejo asesor para el emprendimiento de la Universidad de Cornell, donde Santomauro obtuvo su maestría en Administración de Empresas y licenciatura en artes.

Santomauro será honrado en la ceremonia de premiación en el SugarHouse Casino en Filadelfia, el jueves 10 de mayo.

Acerca de Ancillare, LP

Ancillare es la única organización de su tipo con un enfoque exclusivo en la cadena de suministro clínica y complementaria. Ancillare permite que los patrocinadores de ensayos clínicos globales cuenten con el Plan de Suministro Ancillare, personalizado e integral, que permite a los desarrolladores de nuevas terapias optimizar las cadenas de suministro de sus ensayos clínicos, utilizando procesos perfeccionados, una extensa capacidad de compra global, una amplia red de almacenes y equipos de expertos en áreas clínicas, de abastecimiento, operaciones, logística y reglamentación. El modelo de operaciones llave en mano de Ancillare (A-TKO™) abarca las complejidades y globalización de la cadena de suministro clínica y complementaria global, reduciendo, tanto el coste general, como el tiempo de ciclo de los ensayos clínicos, y mejorando significativamente la eficiencia operacional en todos los niveles de la cadena de valor.

Ancillare ha apoyado más de 1500 ensayos clínicos en más de 80.000 instalaciones clínicas de más de 100 países, con almacenes principales en Estados Unidos, Reino Unido y Singapur, y almacenes estratégicos en Argentina, Australia, Brasil, Canadá, Chile, China, Colombia, India, Israel, Japón, Corea, México, Panamá, Perú, Filipinas, Rusia, Suráfrica, Taiwán y Ucrania. Para conocer más, visite Ancillare.com.

 

Approaching Brexit deadline, new licensure will enable continuous global clinical trial operations for sponsors and CROs

HORSHAM, PA. — January 31, 2018. Global Clinical and Ancillary Supply Chain leader Ancillare, LP, the only organization exclusively serving the end-to-end clinical and ancillary supply chain management needs of large- and middle-market pharmaceutical, biotechnology, and medical device companies, as well as contract and medical research organizations, today announced it has been awarded a Wholesale Distribution Authorization (WDA) for Human use by the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA).

The award, which comes in response to the United Kingdom’s anticipated departure from the E.U.—commonly called “Brexit”—will allow Ancillare to continue to support study sponsors’ European needs, even while Brexit’s impact on pharmaceutical supply chains remains unclear. The licensure is a critical victory for the dozens of study sponsors, CROs and MROs for whom the U.K. market is a vital link in complex, global clinical trial portfolios and supply chains.

“I think [the license is] a testament to the integrity and dedication of our global team,” said Joanne Santomauro, CEO, Ancillare. “No matter how rapidly or exponentially things have changed on the global stage, we’ll always be ready to respond in service to our sponsors.”

Ancillare received the license following an intensive evaluation, auditing and inspections process. Among the qualifying criteria for the license was that Ancillare was in full compliance with the 2012 Human Medicines Regulations, and with the requirements of Good Distribution Practice (GDP). Ancillare’s WDA will enable ongoing wholesaling and distribution activities—including procurement, holding, supply and export—from its European regional office and master depot in Milton Keynes.

“I’m proud that Ancillare has emerged even better equipped to meet the clinical and ancillary supply chain needs of study sponsors,” Santomauro added.

In response to its confirmed regulatory compliance status, as well as ongoing Brexit requirements, Ancillare anticipates adding staff at its United Kingdom office, in order to drive global expansion efforts throughout Europe, the Middle East, Africa and Asia-Pacific. Ancillare expects to announce the staff changes later in Q1 2018.

 

About Ancillare, LP

Ancillare is the only organization of its kind with an exclusive focus on the global clinical and ancillary supply chain. Ancillare arms sponsors of global clinical trials with a customized, end-to-end Ancillare Supply Plan, enabling developers of new therapies to optimize their clinical study supply chains using streamlined processes, extensive global buying power, a vast depot network and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s Turn-Key Operations (A-TKO™) model embraces the complexities and globalization of the clinical and ancillary supply chain by reducing both the overall cost and cycle time of clinical trials, and greatly improving operational efficiency across all levels of the value chain.

Ancillare has supported more than 1,500 clinical trials across 80,000 clinical sites over 100 countries with master depots in United States, United Kingdom, and Singapore, and strategic depots in Argentina, Australia, Brazil, Canada, Chile, China, Colombia, India, Israel, Japan, Korea, Mexico, Panama, Peru, Philippines, Russia, South Africa, Taiwan, and Ukraine. To learn more, visit ancillare.com.

HORSHAM, PA. — Global Clinical and Ancillary Supply Chain leader Ancillare, LP—the only organization exclusively serving the end-to-end clinical and ancillary supply chain management needs of large- and middle-market pharmaceutical, biotechnology, and medical device companies, as well as contract and medical research organizations—today announced that David J. DelCollo, Esq., its primary in-house counsel, has been awarded both “Top 100 Lawyer” and “Top 40 Under 40” recognitions.

The recognitions come on the heels of DelCollo’s first year as Ancillare’s general counsel. Prior to joining Ancillare, he served as Senior Counsel for Bioclinica, where he worked to develop and protect the company’s intellectual property and licensing rights. DelCollo brought more than a decade of legal experience in practice areas such as corporate, contract and healthcare law to Ancillare—knowledge which he made quick use of, according to Ancillare leadership.

“David has made tremendous contributions this year and I think these awards are apropos,” said Joanne Santomauro, CEO at Ancillare. “He’s a skilled attorney. Not only as he helped [Ancillare] define our legal policies, he’s put us on a path to a more secure future.”

Prior to his success in corporate law, DelCollo represented the Commonwealth in the courtroom. As an Assistant District Attorney in the Greater Philadelphia Area, he personally prosecuted over 1,000 cases, winning favorable verdicts and outcomes 97% of the time.

DelCollo holds a J.D. from Widener University School of Law, where he was a member of the Trial Advocacy team.

The recognition of “Top 100 Lawyer” was awarded by executive profile publication International Top 100 Magazine. DelCollo’s “Top 40 Under 40” spotlight will be featured a forthcoming 2018 edition of the same magazine.

About Ancillare, LP

Ancillare is the only organization of its kind with a singular focus on the global clinical and ancillary supply chain. Ancillare arms sponsors of global clinical trials with a customized, end-to-end Ancillare Supply Plan, enabling developers of new therapies to optimize their clinical study supply chains using streamlined processes, extensive global buying power, a vast depot network and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s A-TKO™ model embraces the complexities and globalization of the clinical and ancillary supply chain by reducing both the overall cost and cycle time of clinical trials, and greatly improves operational efficiency across all levels of the value chain.

Ancillare has experience in working over 100 countries with master depots in United States, United Kingdom, and Singapore, and strategic depots in Argentina, Australia, Brazil, Canada, Chile, China, Colombia, India, Israel, Japan, Korea, Mexico, Panama, Peru, Philippines, Russia, South Africa, Taiwan, and Ukraine.